AVITA Medical, Inc. Stock

Equities

RCEL

US05380C1027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:10:15 2024-05-09 pm EDT 5-day change 1st Jan Change
8.825 USD -1.51% Intraday chart for AVITA Medical, Inc. +1.26% -35.64%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 115M 76.23M Sales 2025 * 164M 108M Capitalization 352M 232M
Net income 2024 * -56M -37.02M Net income 2025 * -17M -11.24M EV / Sales 2024 * 2.88 x
Net cash position 2024 * 19.8M 13.09M Net cash position 2025 * 1.85M 1.23M EV / Sales 2025 * 2.14 x
P/E ratio 2024 *
-6.18 x
P/E ratio 2025 *
-31.1 x
Employees 207
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.3%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AVITA Medical, Inc.

1 day-1.45%
1 week+1.26%
Current month+5.12%
1 month-41.02%
3 months-50.94%
6 months-10.63%
Current year-35.64%
More quotes
1 week
8.53
Extreme 8.525
9.64
1 month
8.01
Extreme 8.01
14.67
Current year
8.01
Extreme 8.01
18.93
1 year
8.01
Extreme 8.01
21.70
3 years
4.41
Extreme 4.4102
22.49
5 years
4.41
Extreme 4.4102
55.35
10 years
3.75
Extreme 3.75
55.35
More quotes
Date Price Change Volume
24-05-09 8.84 -1.34% 198 121
24-05-08 8.96 -4.38% 371,776
24-05-07 9.37 +5.28% 171,445
24-05-06 8.9 +1.71% 131,256
24-05-03 8.75 +0.34% 142,531

Delayed Quote Nasdaq, May 09, 2024 at 01:54 pm EDT

More quotes
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.63 AUD
Average target price
39.74 AUD
Spread / Average Target
+191.54%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW